CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Treatments for metastatic pancreatic cancer
The following are treatment options for metastatic pancreatic cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
Chemotherapy is usually offered for metastatic pancreatic cancer.
Chemotherapy drugs and drug combinations used to treat metastatic cancer include:
- gemcitabine (Gemzar)
- FOLFIRINOX – folinic acid (leucovorin), 5-fluorouracil (Adrucil, 5-FU), irinotecan (Camptosar) and oxaliplatin (Eloxatin)
- gemcitabine and nab-paclitaxel (Abraxane)
You may be offered surgery to relieve symptoms of metastatic pancreatic cancer (called palliative surgery).
Stent placement is one of the most common ways to relieve a blockage caused by a pancreatic tumour. A stent is a thin, hollow tube that is placed into the duct to keep it open.
Surgical bypass may be used in some cases. There are different types of surgical bypass used depending on the location of the blockage.
You may be offered radiation therapy to control pain from metastatic pancreatic cancer (called palliative therapy).
If you can’t have or don’t want cancer treatment
You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don’t work anymore, they’re not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don’t want cancer treatment.
Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.
Some clinical trials in Canada are open to people with pancreatic cancer. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
How can you stop cancer before it starts?
Discover how 16 factors affect your cancer risk and how you can take action with our interactive tool – It’s My Life! Presented in partnership with Desjardins.